News round-up for 18 – 22 May by Bruno Quinney, Content Team at DDW. This week, a report showed patients in Europe face barriers to patient access. Elsewhere, Wellcome prizes are facilitating research in both tropical disease and mental health. The… Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, research uncovered new treatment pathways for hard to treat breast cancers. Elsewhere,… Read More
News round-up for 11 – 15 May by Bruno Quinney, Content Team at DDW. This week, research has uncovered new treatment pathways for hard to treat breast cancers. Elsewhere, therapies given the green light could combat type 2 diabetes and generalised myasthenia gravis. The top stories: … Read More
AI tools are scaling flaws in clinical trials instead of solving them, analysis shows. Analytics and data company Phesi revealed the findings from a global analysis of more than 600,000 clinical trial protocols. Results show fewer than one in three (29.3%) protocols are linked to publicly documented patient… Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a new report found breast cancer was the world’s most studied disease… Read More
News round-up for 5 – 9 January by Bruno Quinney, Content Team at DDW. This week in DDW, a new report finds breast cancer is the world’s most studied disease for the fifth year running. That same report predicts obesity to break into the top five, with weight loss a key theme across… Read More
Breast cancer is the most studied disease globally for a fifth year running, a new report reveals. Phesi’s annual report into the world’s most studied diseases found that breast cancer was the most studied across all subtypes, from triple-negative to PIK3CA. Also in the top five were solid tumours, strokes,… Read More
Phesi has released the results of its annual global analysis of all clinical trials conducted in 2024, using data from its AI-driven Trial Accelerator platform (Figure 1). The analysis of 67,469 recruiting clinical trials reveals that breast cancer is the world’s most studied disease for the fourth consecutive year… Read More
A significant number of Phase III clinical trials are over-collecting data because of overcomplicated protocol designs, leading to avoidable delays in drug development times, says a new report. Phesi used proprietary data from its Trial Accelerator Platform to analyse 2,401 industry-sponsored Phase III clinical trials that have… Read More
Covid-19 is no longer in the top five most studied indications, replaced by type 2 diabetes, according to Phesi’s mid-year analysis of clinical trials. The analysis of 66,935 clinical trials reveals that the top five most studied diseases are now breast cancer, solid tumours, stroke, prostate… Read More
A new study demonstrates that AI-powered digital twin solutions can potentially replace the standard-of-care (SOC) control arm of a clinical trial. The paper was co-authored by analytics company Phesi and Dr Yi-Bin Chen, Director for the Blood and Marrow Transplant Program at Massachusetts General Hospital. Read More
DDW’s Megan Thomas spoke to experts from the drug discovery industry about their predictions on what 2024 holds for our sector. This is part of a series of predictions based on different themes. Here, experts weigh in on what to expect from cancer research and immunotherapies. Greg Rossi, Senior Vice… Read More
Breast cancer was the most studied disease in 2023 for the third consecutive year, followed by solid tumours, stroke, Covid-19 and prostate cancer. The analysis of 65,749 recruiting clinical trials was conducted by data analytics company Phesi, as part of an annual global analysis of clinical… Read More
